1. Home
  2. VALN vs NRIX Comparison

VALN vs NRIX Comparison

Compare VALN & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VALN
  • NRIX
  • Stock Information
  • Founded
  • VALN 2012
  • NRIX 2009
  • Country
  • VALN France
  • NRIX United States
  • Employees
  • VALN N/A
  • NRIX N/A
  • Industry
  • VALN Biotechnology: Biological Products (No Diagnostic Substances)
  • NRIX Biotechnology: Pharmaceutical Preparations
  • Sector
  • VALN Health Care
  • NRIX Health Care
  • Exchange
  • VALN Nasdaq
  • NRIX Nasdaq
  • Market Cap
  • VALN 777.9M
  • NRIX 750.4M
  • IPO Year
  • VALN 2021
  • NRIX 2020
  • Fundamental
  • Price
  • VALN $10.44
  • NRIX $9.60
  • Analyst Decision
  • VALN Strong Buy
  • NRIX Strong Buy
  • Analyst Count
  • VALN 4
  • NRIX 14
  • Target Price
  • VALN $15.75
  • NRIX $28.14
  • AVG Volume (30 Days)
  • VALN 77.5K
  • NRIX 1.3M
  • Earning Date
  • VALN 11-06-2025
  • NRIX 10-09-2025
  • Dividend Yield
  • VALN N/A
  • NRIX N/A
  • EPS Growth
  • VALN N/A
  • NRIX N/A
  • EPS
  • VALN N/A
  • NRIX N/A
  • Revenue
  • VALN $230,566,060.00
  • NRIX $83,687,000.00
  • Revenue This Year
  • VALN $15.69
  • NRIX $78.20
  • Revenue Next Year
  • VALN $22.15
  • NRIX N/A
  • P/E Ratio
  • VALN N/A
  • NRIX N/A
  • Revenue Growth
  • VALN 25.47
  • NRIX 48.32
  • 52 Week Low
  • VALN $3.62
  • NRIX $8.18
  • 52 Week High
  • VALN $12.25
  • NRIX $29.56
  • Technical
  • Relative Strength Index (RSI)
  • VALN 51.09
  • NRIX 51.43
  • Support Level
  • VALN $10.08
  • NRIX $9.00
  • Resistance Level
  • VALN $11.35
  • NRIX $10.87
  • Average True Range (ATR)
  • VALN 0.43
  • NRIX 0.61
  • MACD
  • VALN -0.13
  • NRIX 0.12
  • Stochastic Oscillator
  • VALN 29.25
  • NRIX 53.08

About VALN Valneva SE

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.

About NRIX Nurix Therapeutics Inc. Common stock

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Share on Social Networks: